Monoclonal antibody · Antagonist of CD47 · developed by Hutchmed
HMPL-A83 is a humanized IgG4 monoclonal antibody that binds CD47 on tumor cells and blocks its interaction with SIRPa on phagocytic cells. This relieves inhibition of macrophage activation and allows calreticulin-LRP-1 signaling that drives phagocytosis of tumor cells. It is studied in advanced tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05429008 | Phase 1 | Advanced Tumors | Completed | HCM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Tumors
Updated Oct 18, 2026. Something wrong or missing? Report it on the HCM page.
See HCM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HCM catalysts and pipeline →